R:GEN - Macular Laser for Healthy RPE Regeneration
R:GEN is the only retinal laser proven to deliver safe, efficacious and precise targeting of Retinal Pigment Epithelium (RPE) cells. R:GEN’s proprietary Real-Time Feedback, Dual Dosimetry, and Auto Ramp-up technologies ensure precise targeting of RPE cells without damage to photoreceptors.
The R:GEN 527 nm laser with 1.7 μs pulse width provides ideal energy to selectively target the RPE cells while minimizing thermal damage.
Real-time Feedback ensures safety using Dual Dosimetry and Auto-ramping TechnologiesR:GEN utilizes pioneering and proprietary technology to enhance clinical outcomes and safety.
Dual Dosimetry TechnologyR:GEN’s patented Dual Dosimetry Technology utilizes reflectomery (back-scattered light) and opto-acoustic signaling (thermoeleastic pressure waves) to precisely monitor the exact timing of RPE cell destruction. As a result, treatments even within the fovea become possible.
Auto Ramp-up TechnologyThe proprietary Dual Dosimetry function works in tandem with automatic ramping of laser pulse energy. Incremental pulse energy ramping allow treatments to stop at the exact point of RPE cell destruction, and are therefore optimized for every patient and every treatment.
RPE Regeneration ProcessR:GEN selectively targets and causes mechanical disruption of RPE cells without damaging photoreceptors, resulting in the regeneration of new and healthy RPE cells. Rather than causing gross thermal damage to the neural retina, choroid, and photoreceptors, R:GEN triggers new cell growth and repair of function.
- FDA: Clinically Significant Macular Edema (CSME)
- CE Mark: Central Serous Chorioretinopathy (CSC) & Diabetic Macular Edema (DME)
- Korea - MFDS: Central Serous Chorioretinopathy (CSC) & Diabetic Macular Edema (DME)
R:GEN treatment targeting the peripheral area of leakage has shown favorable visual and structural outcomes in chronic CSC patients without causing scotoma.
Resolution of SRF/PED and Safety of the Treatment
Change of best-correct visual acuity (BCVA) (logMAR) in R:GENtreated patients with chronic central serous chorioretinopathy (CSC). Error bars represent standard deviation (SD). The difference of BCVA (logMAR) was statistically significant at 2 and 3 months after SRT. *P<0.05.
Reference: Roh et al. Graefes Arch Clin Exp Ophthalmol (2016). DOI 10.1007/s00417-015-3262-1
R:GEN has been shown to be an effective and safe treatment of clinically significant DME, it shows functional and anatomical improvement or stabilization in 84% of patients.
Reduction of hard exudates and retinal thickness before and 6 months after the treatment
Mean BCVA improved from 43.7 letters (standard deviation,
SD=9.1) at baseline to 46.1 letters (SD=10.5) at the 6-month
follow-up (p=0.02).